KOSPIBiotech & Pharma007460

Aprogen

₩1,730▼ 1.42%2026-11-18 close
Market Cap
₩44.4B
Turnover
₩100M
Volume
70K
Shares out.
25.7M
PER
—
PBR
0.5×
EPS
-₩4,502
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Shorter biosimilar path amid persistent losses

Aprogen's talks to skip a Phase 3 trial for AP063 advanced in both Europe and the US, but five straight quarters of losses through the third quarter of 2026 and reliance on convertible bonds continue.

  1. 1

    Revenue peaked at KRW 150.6 billion in 2023, then fell to KRW 150.1 billion in 2024 and KRW 118 billion in 2025, a decline for two consecutive years.

  2. 2

    The company has posted operating losses for four consecutive years through 2025, and the third-quarter 2026 operating loss narrowed to KRW 13.3 billion from a year earlier.

  3. 3

    The third-quarter 2026 net loss attributable to controlling shareholders widened to KRW 38.5 billion, and the four-quarter total reached KRW 99.6 billion.

  4. 4

    Aprogen said AP063 can move toward marketing applications without a confirmatory Phase 3 trial, following consultations with the EMA and FDA.

  5. 5

    Operating cash flow was KRW -32.7 billion in 2025, and press reports noted that convertible bonds totaling KRW 281 billion were issued across ten tranches.

02

Business structure

Aprogen operates in biopharmaceutical development (biosimilars and antibody drugs) alongside non-pharma businesses that account for a meaningful share of consolidated revenue.

According to a Butler company profile, pharmaceuticals made up 43% of revenue on a second-quarter 2026 basis, followed by hardfacing at 23%, semiconductor equipment parts at 22%, renewable energy at 10%, and insulation at 3%.

Another aggregator, JobKorea, uses different categories such as synthetic drugs, hardfacing and vacuum valves with different weights, so segment shares vary by source.

According to the Q1 2026 quarterly report, AP063 (a Herceptin biosimilar) has completed a global Phase 1 study and is preparing an EMA marketing authorization application.

AP096 (a Humira biosimilar) and AP056 (a Rituxan biosimilar) are at the Phase 1 preparation stage, while GS071 (a Remicade biosimilar) has completed a global Phase 3 study and is under review in Japan and parts of Latin America.

Among novel candidates, AP20 (osteoarthritis) was slated for an IND submission in Q1 2026, and AP40, AP70, AP10 and APN01 are being pursued for out-licensing. The company said in November 2025 that its bispecific AP10, targeting acute myeloid leukemia, achieved complete remission in animal models.

Its subsidiary Aprogen Biologics is listed, and Aprogen held 56.9% of it as of March 31, 2026; the subsidiary provides CDMO services from its Osong plant in Chungbuk. In biosimilars, Aprogen competes with Celltrion, Samsung Epis Holdings and Alteogen, while in contract manufacturing it overlaps with Samsung Biologics.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩35.6B-₩22.3B−62.7%
2025Q4₩31.5B-₩26.9B−85.4%
2026Q1₩36.3B-₩20.6B−56.8%
2026Q2₩35.5B-₩22.4B−63.2%
2026Q3₩34.6B-₩13.3B−38.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩78.3B-₩119.3B-₩98.7B−152.3%−45.9%30.1%
2023₩150.6B-₩88.9B-₩55.6B−59.0%−37.6%42.3%
2024₩150.1B-₩86.8B-₩58.1B−57.8%−36.6%38.6%
2025₩118B-₩95.6B-₩70.2B−81.0%−44.3%56.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose 92.2% from KRW 78.3 billion in 2022 to KRW 150.6 billion in 2023, the largest year in the 2022–2025 window. Revenue then fell 0.3% to KRW 150.1 billion in 2024 and 21.4% to KRW 118 billion in 2025, a decline for two consecutive years.

Operating losses were KRW 119.3 billion in 2022, KRW 88.9 billion in 2023, KRW 86.8 billion in 2024 and KRW 95.6 billion in 2025, so the company has been loss-making for four consecutive years, with the loss widening again in 2025.

The operating margin improved from -152.3% in 2022 to -59.0% in 2023 and -57.8% in 2024, then deteriorated to -81.0% in 2025. The net loss attributable to controlling shareholders narrowed from KRW 98.7 billion in 2022 to KRW 55.6 billion in 2023, then widened to KRW 58.1 billion in 2024 and KRW 70.2 billion in 2025.

The consolidated net loss, which includes non-controlling interests, was KRW 140.6 billion in 2025, a much larger figure than the controlling-shareholder figure.

The debt ratio rose from 30.1% in 2022 to 56.4% in 2025, with total liabilities of KRW 258.7 billion at the end of 2025 against total equity of KRW 458.6 billion, of which KRW 158.3 billion belonged to controlling shareholders.

Operating cash outflow narrowed from KRW -113.5 billion in 2022 to KRW -32.7 billion in 2025, but it has been negative in each of the four years. Data Daily reported that receivables reached KRW 61.22 billion in 2025, up 148.7% year on year even as revenue declined.

On a quarterly basis, revenue fell from KRW 35.6 billion in the third quarter of 2025 to KRW 31.5 billion in the fourth quarter, recovered to KRW 36.3 billion in the first quarter of 2026, then declined to KRW 35.5 billion in the second quarter and KRW 34.6 billion in the third quarter of 2026.

The operating loss narrowed to KRW 13.3 billion in the third quarter of 2026 from KRW 22.4 billion in the second quarter, while the net loss attributable to controlling shareholders widened from KRW 25.5 billion to KRW 38.5 billion over the same period.

Medico Pharma reported that the subsidiary Aprogen Biologics booked only about KRW 0.2 billion of bio manufacturing service revenue in the first quarter of 2026.

05

Industry analysis

In biosimilars, development time and cost are the central variables, and whether a Phase 3 trial can be skipped changes both the approval timeline and the cost structure.

According to a Money Today report, the company expects substantial economic benefits from skipping Phase 3 and says its proprietary production process offers more than six times the productivity of conventional methods. The same report cited analysis that this could support price competitiveness.

However, Korean media reported that the EMA recommended additional dose-response data in healthy adults, which was framed as a recommendation rather than a mandatory condition.

Competitively, the company is compared with Celltrion and Samsung Epis Holdings, which are already commercializing biosimilars, and with Alteogen, which has formulation technology. In contract manufacturing, large players such as Samsung Biologics lead in production scale.

Medico Pharma flagged utilization of the Osong plant at Aprogen Biologics as an open issue. The company presents the Osong plant as a facility with top-tier antibody production capacity globally, but the contract manufacturing revenue confirmed in reports remains small.

The non-pharma businesses, hardfacing and semiconductor equipment parts, follow demand cycles different from biologics, so consolidated results reflect movements in both.

06

Outlook

The talks to skip a Phase 3 trial for AP063 have progressed in both Europe and the US, according to company announcements.

Korean media reported that the EMA indicated in February 2026 that an application could proceed after submission of process performance qualification data without a further confirmatory Phase 3 trial. Money Today reported that a similar position was secured at an FDA pre-BLA meeting in May 2026.

The remaining step is PPQ production, and the company said it plans to start the US biologics license application once supporting data are ready. Because no timing for the BLA start has been set, when approval-related revenue would show up in consolidated results will need to be checked against future disclosures.

A report cited a 2026 bio business revenue forecast of KRW 167.2 billion for the subsidiary Aprogen Biologics, while its first-quarter 2026 manufacturing service revenue was about KRW 0.2 billion. How quickly that gap narrows is the checkpoint for the subsidiary's plant utilization.

The pipeline outlook includes the planned AP20 IND submission and out-licensing efforts for the remaining candidates. On funding, in April 2026 the subsidiary decided on a third-party allotment of roughly KRW 2 billion to Aprogen as its largest shareholder. A further subsidiary rights-offering decision was disclosed on September 3, 2026, according to Data Daily.

07

Valuation

PER
—
PBR
0.5×
ROE
-88.1%
EPS
-₩4,502
BPS
₩3,114
Dividend per share
₩0

Because the company has posted net losses over the most recent four quarters, its PER cannot be calculated. The price-to-book ratio sits below 1x, which means the shares trade at a discount to net asset value.

Still, of total equity of KRW 458.6 billion, only KRW 158.3 billion belongs to controlling shareholders, so the choice of base, total equity or controlling-shareholder equity, changes how the ratio reads.

A large non-controlling interest means consolidated equity depends heavily on the subsidiary structure, which also needs to be considered. The dividend yield is effectively negligible and sits below the sector average.

Because PER comparisons with listed peers are not meaningful during a loss period, book-value multiples and the trend in operating indicators become the main points of comparison. When losses shrink the equity base, a low multiple may reflect how much asset value remains, which needs separate assessment. Past PER bands are difficult to apply here because of the extended loss-making period.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Progress on skipping Phase 3

The company said it secured a position from the FDA, after the EMA, that AP063 could move toward a marketing application without a confirmatory Phase 3 trial. The remaining steps are PPQ production and starting the BLA. The company argues that avoiding this trial would reduce cost and time.

Narrowing operating loss

The operating loss for the third quarter of 2026 was KRW 13.3 billion, down from KRW 22.4 billion in the second quarter and smaller than a year earlier. Quarterly losses have moved in both directions since 2025. Whether the narrowing continues is the key point to watch.

Diversified pipeline and plant

The company holds several biosimilar candidates alongside bispecific and other novel programs, so it does not rely on a single product. The Osong plant at the subsidiary is presented by the company as having top-tier antibody capacity. If contract manufacturing orders grow, utilization could improve.

09

Bear factors

Revenue down two straight years

Revenue fell from KRW 150.6 billion in 2023 to KRW 150.1 billion in 2024 and KRW 118 billion in 2025, a 21.4% drop in the latter year. Quarterly revenue declined again in the second and third quarters of 2026. Bio manufacturing revenue is still limited, so the basis for a revenue recovery is not yet clear.

Reliance on external funding

Operating cash outflow was KRW -32.7 billion in 2025, negative in each of the four years. Data Daily reported convertible bonds issued across ten tranches totaling KRW 281 billion. A subsidiary rights-offering decision on September 3, 2026 keeps dilution concerns in focus.

Subsidiary utilization and cumulative losses

Aprogen Biologics booked only about KRW 0.2 billion of bio manufacturing service revenue in the first quarter of 2026, and bio production output was recorded at zero liters in both 2025 and that quarter, according to Medico Pharma.

The four-quarter total net loss attributable to controlling shareholders is KRW 99.6 billion. Because the subsidiary's performance feeds into consolidated results, the burden is significant.

10

Risk factors

Funding and dilution

With operating losses continuing, the company relies on convertible bonds and rights offerings. Conversion of bonds into shares could lower existing shareholders' stake. Future disclosures on financing terms and conversion prices will need to be monitored.

Approval and regulatory timing

The EMA recommended additional dose-response data in healthy adults, though it was framed as a recommendation rather than a requirement. PPQ production and the BLA start have no confirmed timing until the company announces them. Regulators' final decisions could differ from earlier consultations, leaving room for delays.

Business mix and concentration

On a second-quarter 2026 basis, hardfacing and semiconductor equipment parts accounted for 45% of revenue, so non-biologics businesses carry substantial weight. Segment shares differ by aggregator, which makes the earnings structure hard to read from one source. If biologics monetization is delayed, reliance on non-pharma results could last longer.

11

What to watch next

  1. Late March 2027

    Annual report for fiscal 2026. Confirmed full-year revenue, operating and controlling-shareholder net results, and the year-end debt and equity structure will be checked here.

  2. Timing not set (on company announcement)

    Completion of PPQ production for AP063 and whether the US BLA is filed. Actual filing is the key milestone for pipeline progress.

  3. Late March 2027

    Subsidiary Aprogen Biologics' fiscal 2026 annual report, which will show manufacturing service revenue and Osong plant utilization.

12

Overall view

Aprogen has advanced the approval path for AP063 after reaching talks in both Europe and the US to skip a Phase 3 trial. Revenue, however, fell in 2024 and 2025, and operating losses have continued for four consecutive years.

The third-quarter 2026 operating loss narrowed to KRW 13.3 billion, while the net loss attributable to controlling shareholders widened to KRW 38.5 billion. Operating cash outflow has persisted for four years, and the company continues to depend on convertible bonds and rights offerings.

The subsidiary's Osong plant is presented as a strength, yet its first-quarter 2026 manufacturing service revenue was only about KRW 0.2 billion. Strengths include regulatory progress and a narrower operating loss, while weaknesses include declining revenue and reliance on external funding.

The next checkpoints are the fiscal 2026 annual results and cash flow, whether the US BLA is filed for AP063, and changes in subsidiary plant utilization.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.wisereport.co.kr
  2. jobkorea.co.kr
  3. kind.krx.co.kr
  4. eduinfom.com
  5. medicopharma.co.kr
  6. comp.fnguide.com
  7. theinvest.co.kr
  8. butler.works
  9. news.nate.com
  10. dailyan.com
  11. markets.hankyung.com
  12. thevc.kr
  13. aprogen-biologics.com
  14. pharm.edaily.co.kr
  15. news.nate.com
  16. mt.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis